JUAN J. PLAZA, M.D.; GABRIEL HERRERO, M.D.; ANTONIO BARAT, Ph.D.; JUAN J. LOUTAIF, M.D.; LUIS HERNANDO, Ph.D.; PEDRO VALLADO, M.D.; HORACIO OLIVA, Ph.D.
Parenteral gold compounds are usually successful in the treatment of patients with rheumatoid arthritis, but renal complications such as transient proteinuria and nephrotic syndrome (affecting 10% to 31% and 0.2% to 2.6% of patients, respectively) sometimes force discontinuation of the treatment (1, 2).
Auronafin (Smith Kline & French Laboratories, Philadelphia, Pennsylvania), an oral preparation containing gold (2, 3, 4, 6 tetra-O-acetyl-l-thio-B-D-glucopyranosato-s) (triethyl phosphine) has been proposed to be as effective as the injectable compounds with the additional advantage of being almost free from side effects; microscopic haematuria and proteinuria have occurred rarely. (Smith Kline & French Laboratories; data on file.)
PLAZA JJ, HERRERO G, BARAT A, LOUTAIF JJ, HERNANDO L, VALLADO P, et al. Membranous Glomerulonephritis as a Complication of Oral Gold Therapy. Ann Intern Med. ;97:563–564. doi: 10.7326/0003-4819-97-4-563
Download citation file:
Published: Ann Intern Med. 1982;97(4):563-564.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use